Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

155 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators goal is to measure the impact of timing of postpartum contraceptive implant insertion on breastfeeding success and duration and to explore women's experiences with and attitudes towards contraceptive and breastfeeding counseling in the peripartum time period

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Labor and Delivery Implant Insertion: A Randomized Controlled Trial

NCT02866643

Postpartum Contraception Family Planning

COMPLETED PHASE3

The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth

NCT01388582

Underweight

COMPLETED PHASE4

Etonogestrel Implant and Postpartum Insertion

NCT02416687

Contraception

COMPLETED PHASE4

Breastfeeding Etonogestrel Implant Study

NCT03978598

Contraception

COMPLETED PHASE4

Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial

NCT01465022

Breast Feeding Contraception

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immediate postpartum initiation of the etonogestrel contraceptive implant has been proven to decrease rates of rapid, repeat pregnancies. Evidence supports that in healthy women with term infants initiation of the contraceptive implant 1-3 days postpartum does not appear to have any adverse effects on lactogenesis or breastfeeding continuation. However, no high quality study to date has examined the effects of progestin-only contraception in women known to be at risk for low milk supply, including women with a premature delivery, obesity, polycystic ovarian syndrome, diabetes, or a prior history of low milk supply.

The investigators goal is to measure the impact of timing of postpartum contraceptive implant insertion on breastfeeding success and duration. This will be a three-armed randomized non-inferiority study of women who plan to breastfeed, have known risk factors for low milk supply, and who intend to use the contraceptive implant postpartum. Women will be randomized to one of three groups for the timing of contraceptive implant placement: within 30 minutes of placental delivery, 24-72 hours postpartum, or 6 or more weeks postpartum. Women will be assessed at 6 weeks, 3 months and 6 months postpartum. Outcomes will include time to Lactogenesis Stage II, duration and exclusivity of breastfeeding, continuation of and satisfaction with the contraceptive implant, and side effects, including bleeding patterns, associated with the implant.

Findings from this trial will be used by clinicians, hospital systems, and policy makers working to expand access to immediate postpartum implants while supporting women in meeting their breastfeeding goals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception Breastfeeding Postpartum Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Postplacental

contraceptive implant placed within 30 minutes of placental delivery

Group Type EXPERIMENTAL

Etonogestrel Contraceptive Implant

Intervention Type DEVICE

Women will be randomized to the TIMING of implant placement

Immediate Postpartum

Contraceptive Implant placed 1-3 days postpartum

Group Type EXPERIMENTAL

Etonogestrel Contraceptive Implant

Intervention Type DEVICE

Women will be randomized to the TIMING of implant placement

Delayed

Contraceptive Implant placed 6 or more weeks postpartum

Group Type ACTIVE_COMPARATOR

Etonogestrel Contraceptive Implant

Intervention Type DEVICE

Women will be randomized to the TIMING of implant placement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etonogestrel Contraceptive Implant

Women will be randomized to the TIMING of implant placement

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nexplanon

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Live pregnancy of at least 24 weeks gestation
* Intention to use a contraceptive implant postpartum
* 17 years of age or older
* English or Spanish speaking
* Admission to Labor and Delivery with a plan for delivery (women in both latent and active labor will be eligible)
* The presence of at least one of the following conditions known to be a risk factor for low milk supply:

* Expected delivery prior to 34 weeks
* Obesity (pre-pregnancy BMI \>35)
* Polycystic Ovarian Syndrome
* Diabetes (gestational or pre-gestational)
* Self-reported difficulty with low milk supply in past